MedTrace Logo

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

NCT01137799 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2012-11-08

No results posted yet for this study

Summary

This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential \[AEP\] P50, AEP P300 and Mismatch Negativity \[MMN\]) after single dose administration.

Conditions

Interventions

DRUG

JNJ-39393406

50mg nanosuspension (sort of liquid formulation) once daily (single dose)

DRUG

placebo

Once daily (single dose)

DRUG

JNJ-39393406

200mg nanosuspension (sort of liquid formulation) once daily (single dose)

DRUG

JNJ-39393406

100mg nanosuspension (sort of liquid formulation) once daily (single dose)

DRUG

JNJ-39393406

10mg nanosuspension (sort of liquid formulation) once daily (single dose)

DRUG

JNJ-39393406

30mg nanosuspension (sort of liquid formulation) once daily (single dose)

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutica N.V. Clinical Trial · Janssen Pharmaceutica N.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Completion
2011-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01137799 on ClinicalTrials.gov